Neurocrine/$NBIX
Neurocrine jumps after announcing a collaboration with TransThera Sciences for exclusive rights to develop and commercialize preclinical NLRP3 inhibitors in a deal worth up to $881.5 million.
16 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Ticker
$NBIX
Sector
Primary listing
Employees
1,800
Headquarters
Website
Neurocrine Metrics
BasicAdvanced
$15B
36.68
$4.19
0.21
-
Price and volume
Market cap
$15B
Beta
0.21
52-week high
$157.67
52-week low
$84.23
Average daily volume
1M
Financial strength
Current ratio
3.383
Quick ratio
2.888
Long term debt to equity
14.263
Total debt to equity
15.971
Profitability
EBITDA (TTM)
570
Gross margin (TTM)
63.21%
Net profit margin (TTM)
15.95%
Operating margin (TTM)
20.14%
Effective tax rate (TTM)
31.91%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
8.66%
Return on equity (TTM)
14.96%
Valuation
Price to earnings (TTM)
36.68
Price to revenue (TTM)
5.698
Price to book
5.1
Price to tangible book (TTM)
5.16
Price to free cash flow (TTM)
25.774
Free cash flow yield (TTM)
3.88%
Free cash flow per share (TTM)
5.965
Growth
Revenue change (TTM)
19.61%
Earnings per share change (TTM)
12.44%
3-year revenue growth (CAGR)
24.54%
10-year revenue growth (CAGR)
63.40%
3-year earnings per share growth (CAGR)
91.07%
10-year earnings per share growth (CAGR)
15.83%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Bulls say / Bears say
Neurocrine posted Q2 2025 net product sales of $682 million, up 17% year-over-year, led by $624 million from INGREZZA and $53 million from CRENESSITY.
After positive Phase 2 results from the SAVITRI study, Neurocrine launched a Phase 3 registrational program for osavampator as an add-on therapy in major depressive disorder in January 2025.
The company finished a $300 million accelerated share repurchase in February 2025 and its board authorized a new $500 million buyback plan, with $332.3 million still available as of September 30, 2025.
Investors are worried that higher spending on expanding the salesforce could hurt operating margins, leading to a 6.4% drop in the stock after Q3 results.
Analysts note that INGREZZA faces pricing pressure and that a Department of Justice investigation represents ongoing regulatory and net price risks for Neurocrine’s main product.
Neurocrine insiders have sold over 227,000 shares in the last six months, with no insider purchases reported; notably, CEO Kyle Gano sold 70,079 shares, pointing to possible insider pessimism.
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $15B as of November 06, 2025.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 36.68 as of November 06, 2025.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.